At Centauri we seek to tackle life-threatening infectious diseases in the most vulnerable patients.

Learn more
Alphamers

Our science

Centauri Therapeutics is an immunotherapy company focused on infectious diseases. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases. Centauri holds an exclusive worldwide license to exploit the Alphamer® immunotherapeutics platform within the field of infectious disea

7.0m

immunocompromised people in the United States 1

60%

of haematological cancer deaths are infection related 2

$4.6bn

health care costs in the US to treat six antibiotic resistance threats 3

67,000

deaths annually in Europe and US due to drug-resistant bacterial infections 4 5

Bacteria

Latest News and Articles

Centauri Therapeutics attended ID Week 2022

October 27, 2022

Jennifer Schneider, CEO and Helen Bright, VP of Research &…

Read More

Centauri Therapeutics Dr Mike Westby attended ESCMID/ASM Conference 2022

October 27, 2022

Dublin, 4th to 7th October 2022 – Dr Mike Westby, Centauri’s…

Read More

Centauri welcomes Alison Gallop

October 17, 2022

Centauri is pleased to welcome Alison Gallop to the team…

Read More

Citations

1. https://www.ama-assn.org/delivering-care/public-health/what-tell-immunocompromised-patients-about-covid-19-vaccines

2. Zembower, T.R. (2014). Epidemiology of Infections in Cancer Patients. In: Stosor, V., Zembower, T. (eds) Infectious Complications in Cancer Patients. Cancer Treatment and Research, vol 161. Springer, Cham https://doi.org/10.1007/978-3-319-04220-6_2

3. https://www.cdc.gov/drugresistance/solutions-initiative/stories/partnership-estimates-healthcare-cost.html

4. https://www.euro.who.int/en/health-topics/disease-prevention/pages/news/news/2022/01/whoecdc-report-antimicrobial-resistance-remains-threat-to-health-in-european-region

5. https://www.cdc.gov/media/releases/2019/p1113-antibiotic-resistant.html